Small molecule drug developer C4 has fied for a $100m initial public offering, three months after the Dana-Farber Cancer Institute spinout raised a $170m round.
C4 Therapeutics, a US-based small molecule drug developer spun out of the Harvard-affiliated Dana-Farber Cancer Institute, has filed to raise up to $100m in an initial public offering.
C4 is developing treatments for diseases including cancer and various neurodegenerative disorders that are designed to work by degrading disease-causing proteins.
Part of the IPO proceeds will fund part of a phase 1/2 clinical trial for a drug candidate, CFT7455, in multiple myeloma and non-Hodgkin lymphomas – both forms…
